



How I diagnose and treat neutropenia

David C. Dale

Purpose of review

Neutropenia absolute neutrophil count (ANC) less than $1.5 \times 10^9/l$ is a common hematological finding, and severe neutropenia, that is, ANC less than $0.5 \times 10^9/l$ is a well known risk factor for susceptibility to bacterial infections. This review provides a succinct clinical approach to the diagnosis and treatment of neutropenia with specific recommendations on the treatment of severe chronic neutropenia with the myeloid growth factor, granulocyte colony-stimulating factor (G-CSF).

Recent findings

Experts agree that patients with acute febrile neutropenia should be treated with antibiotics and that patients at high risk of severe neutropenia (>20% risk) after myelosuppressive chemotherapy should be treated prophylactically with a myeloid growth factor, usually G-CSF. The diversity of causes and consequences of chronic neutropenia make the diagnosis and management of these patients more complicated.

Summary

The review provides a stepwise approach to neutropenia focusing first on reaching a provisional diagnosis and treatment plan then steps to a final diagnosis. It also provides specific recommendations on the treatment of severe chronic neutropenia with G-CSF.

Keywords

diagnosis, granulocyte colony-stimulating factor, neutropenia, treatment

INTRODUCTION

I have been interested in the diagnosis and treatment of neutropenia for nearly 50 years, from when we had just a few antibiotic choices for managing febrile neutropenia to the present era with a huge array of testing strategies, worries about antibiotic resistance and options for growth factor treatments.

Several experts have recently recommended approaches to acute and chronic neutropenia in children and adults [1^{''},2^{''},3–9] and managing chemotherapy-induced neutropenia, including antibiotic therapy [10^{''},11,12,13^{''},14]. In this brief review, I suggest a stepwise clinical approach to diagnose and treat neutropenia.

- (b) Are there previous blood cell counts (CBCs)? Establish whether neutropenia is acute (days to weeks) or chronic (months to years).
- (c) What is the clinical context? A newborn? Possibly a reaction to a drug? Associated with cancer chemotherapy? Part of an ongoing autoimmune, infectious, or inherited disease?
- (d) What clinical events have occurred: fevers, mouth ulcers, gingivitis, cellulitis, rectal ulcers, pneumonia, abscesses, and/or bacteremia? What is the frequency? Is there a pattern?
- (e) Do any family members have similar illnesses or symptoms?

CLINICAL APPROACH TO NEUTROPENIA

- (1) Always get a complete medical history. The key questions are:
 - (a) Is neutropenia part of an acute illness or was it found on routine examination? If it was found on routine examination and the patient is not ill, making the diagnosis can be deliberative.

Department of Medicine, University of Washington, Seattle, Washington, USA

Correspondence to David C. Dale, MD, Department of Medicine, University of Washington, Box 356422, 1959 NE Pacific St., Seattle, WA 98195, USA. Tel: +1 206 543 7215; e-mail: dcdale@u.washington.edu

Curr Opin Hematol 2016, 23:1–4

DOI:10.1097/MOH.0000000000000208

KEY POINTS

- The study provides a stepwise approach to making the diagnosis in patients presenting with neutropenia.
- Patients with fever and severe neutropenia should always have a careful examination and receive antibiotics as soon as possible.
- Patients with severe chronic neutropenia benefit from treatment with granulocyte colony-stimulating factor (G-CSF); this review gives specific guidelines for treatment of these patients.

- (2) Do a careful exam:
 - (a) Focus on evidence of infection in skin, respiratory tract, abdominal, and perirectal area.
 - (b) Determine whether there is lymphadenopathy or hepatosplenomegaly.
 - (c) Examine carefully for congenital abnormalities.
- (3) Gather laboratory data:
 - (a) If neutropenia appears to be acute, see when counts were last normal and patterns of decline. If neutropenia may be chronic, get CBCs back to early childhood. Usually 20 counts over a 40- to 50-day period are necessary to diagnose cyclic neutropenia.
 - (b) Evaluate each hematological cell lineage, if counts are stable or drifting upward or downward. Neutropenia combined with anemia and/or thrombocytopenia suggests an autoimmune or infectious disease or perhaps a generalized marrow failure disorder. Neutropenia and thrombocytopenia are common with splenic enlargement. Neutropenia and lymphocytopenia occur in autoimmune diseases and idiopathic neutropenia. Severe neutropenia and lymphocytopenia occur in warts, hypogammaglobulinemia, infections and myelokathexis syndrome.
 - (c) Review other laboratory data and imaging studies.
- (4) Form a provisional clinical diagnosis and give initial therapy:
 - (a) Examples are:
 - (i) Acute neutropenia associated with a new medication.
 - (ii) Acute febrile neutropenia after cancer chemotherapy.
 - (iii) Newly recognized fever and severe neutropenia in infant.
 - (iv) Chronic mild neutropenia in asymptomatic adult woman.
 - (b) If the patient is febrile and acutely ill, antibiotics, fluids, and urgent hospital care are usually required. I do not hesitate to recommend myeloid growth factor treatment, that is, G-CSF, especially if the patient has not received it previously [1^{••},2^{••},3–9,10^{••},11,12,13^{••}].
- (5) Make a specific diagnosis:
 - (a) Before a marrow exam: if the diagnosis is not known:
 - (i) Consider antineutrophil antibody testing in children; it is generally not very helpful in adults. If ordered, it is very important to identify a specialized laboratory for this testing. Remember, positive test results may occur in patients with congenital as well as autoimmune neutropenia [3–4].
 - (ii) Consider fluorescence-activated cell sorting analysis to identify a causal clonal hematological disease, for example, large granular lymphocyte syndrome [8].
 - (iii) Consider antinuclear antibody tests. The antinuclear antibody reflexive panel will help to identify patients with autoimmune diseases.
 - (iv) Consider measuring vitamin B12, folate and other vitamin levels; transcobalamin deficiency is a very rare cause of neutropenia [2^{••}].
 - (v) Consider genetic sequencing to identify mutations in genes associated with neutropenia. Mutations in elastase, neutrophil expressed gene (*ELANE*) are by far the most common cause of cyclic and congenital neutropenia. Use evidence of autosomal or recessive inheritance and clinical clues, that is, cardiac or urogenital abnormalities suggest glucose 6-phosphatase, catalytic, 3 gene (*G6PC3*) mutation, malabsorption, short stature suggest Shwachman–Diamond syndrome, etc. Testing for a broad panel of genetic causes for neutropenia [Hematopoietic cell-specific lyn substrate1-Associated protein X-1 (*HAX1*), *G6PC3*, Wiskott-Aldrich Syndrome gene (*WAS*), Shwachman-Bodian-Diamond Syndrome gene (*SBDS*), etc.] is appropriate in children with no associated anomalies to guide testing or when a panel is less expensive than several individual tests [2^{••},3–7].

- (b) Marrow examination:
- (i) A marrow examination is not routinely done for acute chemotherapy or drug-associated neutropenia. It is also not necessary when patients have a long history of mild to moderate-isolated neutropenia. It is very important to diagnose myelodysplasia, acute leukemia, severe neutropenia, or generalized marrow failure.
 - (ii) The differential cell count and cytogenetics are useful tests. In the congenital neutropenias, 'maturation arrest' is the expected finding, but it is not always present, especially if the patient is ill when the test is performed. Usually these tests are sufficient for making the diagnosis. If not and the patient is not very ill, it is best to observe at intervals of 3–6 months or refer.
- (6) Make treatment plan for acute neutropenia:
- (a) Broad spectrum antibiotics are the critical for acutely ill patients with severe neutropenia. The specifics depend on the patient's diagnosis, the severity of illness and the results of microbial cultures [11,12,13¹¹].
 - (b) The availability of G-CSF is the most important advance in the management of neutropenia. There are recent evidence-based guidelines for prevention of infections associated with chemotherapy-induced neutropenia [10¹¹,13¹¹,14].
- (7) Make treatment plan for chronic neutropenia: The use of G-CSF to prevent and treat infections in patients with severe chronic neutropenia differs significantly from the use of this myeloid growth factor for prevention of infection in patients with chemotherapy-induced neutropenia. My recommendations are:
- (a) For chronic neutropenia, the minimal criteria for G-CSF are: absolute neutrophil count repeatedly less than $0.5 \times 10^9/l$ with recurrent mouth ulcers and gum disease. The goal is to prevent pain and loss of permanent teeth. Recurrent fevers, cellulitis, abscesses, sinusitis, pneumonia, perirectal infections are stronger criteria for recommending long-term G-CSF treatment.
 - (b) The use of G-CSF for preventing infections in idiopathic, cyclic, and congenital neutropenia is based on a randomized controlled trial [15]. Effective doses of G-CSF vary by diagnosis (expressed as $\mu\text{g}/\text{kg}/\text{day}$ and given daily, alternate day, or three times per week): idiopathic: median 1.2; cyclic: median 2.4; congenital: median 7.3. Patients with SCN presenting with a serious infection should be administered both G-CSF and antibiotics immediately.
- (c) Patients should be advised that the acute adverse events associated with initiation of G-CSF are primarily bone pain, arthralgias, myalgias, and headache with onset a few hours after the injections [16]. There are less common adverse events including thrombocytopenia, skin rash, injection site reactions, vasculitis, and glomerulonephritis. Decreased bone density and osteoporosis are also reported but pathological fractures are uncommon [16]. The potential for increasing the risk of myeloid leukemia should also be discussed with each patient. Severe congenital neutropenia patients have a high risk of evolving to myelodysplastic syndrome and acute myeloid leukemia [17]. Certain *ELANE* mutations appear to carry a much higher risk [18¹¹].
- (d) For most patients with chronic neutropenia and infections, I recommend:
- (i) Start with a low daily dose of G-CSF. I recommend daily dose for idiopathic $1.0 \mu\text{g}/\text{kg}/\text{day}$, cyclic $2.0 \mu\text{g}/\text{kg}/\text{day}$, and congenital $3.0 \mu\text{g}/\text{kg}/\text{day}$.
 - (ii) Use daily therapy initially, the advantage of daily treatment is to avoid or minimize bone pain and other acute adverse effects.
 - (iii) Switch to every other day on a Monday/Wednesday/Friday schedule for good responders (daily dose $3 \mu\text{g}/\text{kg}/\text{day}$ or less).
 - (iv) If initial therapy is insufficient to reach target median count, increase dose by $1\text{--}2 \mu\text{g}/\text{kg}/\text{day}$ at 1- to 2-week intervals; above $10 \mu\text{g}/\text{kg}/\text{day}$ increase the dose by $3\text{--}5 \mu\text{g}/\text{kg}/\text{day}$ to maximum dose of $20\text{--}30 \mu\text{g}/\text{kg}/\text{day}$. Consult with a neutropenia specialist in all nonresponding or poorly responding patients to consider alternate strategies, including hematopoietic transplantation.
 - (v) Monitor CBC at least weekly in the initial 2 months on treatment, at least once per month for the first 6 months and quarterly thereafter for stable patients.
 - (vi) For severe congenital neutropenia patients, evaluate with bone marrow aspirate and cytogenetics

pretreatment and annually. For others, consult with a neutropenia specialist.

- (vii) Other than G-CSF, hematopoietic transplantation is the only other predictably effective treatment for congenital, cyclic, or idiopathic neutropenia.
- (viii) Patients with autoimmune neutropenia will respond to G-CSF, similar to idiopathic neutropenia.

CONCLUSION

Neutropenia is no longer the challenge it once was to clinicians. The greatest challenge now is to provide truly useful 'point of care' information to clinicians, patients, and families when they need it.

Acknowledgements

We would like to thank Audrey Anna Bolyard for her review of the manuscript.

Financial support and sponsorship

The work was supported by a National Institutes of Health, NIAID grant for the Severe Chronic Neutropenia International Registry, grant # 5R 24AI049393-11, the Amgen Foundation and the Ella Jewell Foundation.

Conflicts of interest

D.C.D. serves as a consultant for Amgen, the manufacturer of granulocyte colony-stimulating factor (G-CSF) products, Neupogen and Neulasta. G-CSF is used for the treatment of neutropenia. The UW has a contract with Amgen. D.C.D. is the PI for this contract. Amgen supplies G-CSF through a research pharmacy directly to patients who are in the NIH sponsored Registry. All of these relationships have been previously revealed in UW GIM 10 forms.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. *Blood* 2014; 124:1251–1258.

A timely review and practical approach to the evaluation of adult neutropenia patients, focusing on the outpatient setting.

2. Palmblad J, Dufour C, Papadaki HA. How we diagnose neutropenia in the adult and elderly patient. *Haematologica* 2014; 99:1130–1133.
- A practical review of the diagnosis and treatment of acute and chronic neutropenia in adults, particularly the elderly, following step by step evaluation and diagnosis in a specific case.
3. Walkovich K, Boxer LA. How to approach neutropenia in childhood. *Pediatr Rev* 2013; 34:173–184.
4. Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. *Sem Hematol* 2013; 50:198–206.
5. Fioredda F, Calvillo M, Bonanomi S, *et al.* Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). *Am J Hematol* 2012; 87:238–243.
6. Fioredda F, Calvillo M, Bonanomi S, *et al.* Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica). *Pediatr Blood Cancer* 2011; 57:10–17.
7. Donadieu J, Fenneteau O, Beaupain B, *et al.* Congenital neutropenia: diagnosis, molecular bases and patient management. *Orphanet J Rare Dis* 2011; 6:26.
8. Lamy T, Loughran TP Jr. How I treat LGL leukemia. *Blood* 2011; 117:2764–2774.
9. Andrés E, Zimmer J, Mecili M, *et al.* Clinical presentation and management of drug-induced agranulocytosis. *Expert Rev Hematol* 2011; 4:143–151.
10. Vehreschild JJ, Böhme A, Cornely OA, *et al.* Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Infectious Diseases Working Party of the Society for Haematology and Medical Oncology. *Ann Oncol* 2014; 25:1709–1718.
- Evidence-based guidelines for the use on myeloid growth factors to prevent infections associated with chemotherapy-induced neutropenia.
11. Averbuch D, Orasch C, Cordonnier C, *et al.* ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. *Haematologica* 2013; 98:1826–1835.
12. Flowers CR, Seidenfeld J, Bow EJ, *et al.* Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2013; 31:794–810.
13. Smith TJ, Bohlke K, Lyman GH, *et al.* Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2015; 33:319–212.
- The most recent evidence-based guidelines for prevention of infections with myeloid growth factors for patients receiving cancer chemotherapy.
14. Crawford J, Armitage J, Balducci L, *et al.* Myeloid growth factors. *J Natl Compr Canc Netw* 2013; 11:1266–1290.
15. Dale DC, Bonilla MA, Davis MW, *et al.* A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. *Blood* 1993; 81:2496–2502.
16. Dale DC, Bolyard AA, Schwinger BG, *et al.* The severe chronic neutropenia international registry: 10-year follow-up report. *Support Cancer Ther* 2006; 3:220–231.
17. Rosenberg PS, Zeidler C, Bolyard AA, *et al.* Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. *Br J Haematol* 2010; 150:196–199.
18. Makaryan V, Zeidler C, Bolyard AA, *et al.* The diversity of mutations and clinical outcomes for *ELANE*-associated neutropenia. *Curr Opin Hematol* 2015; 22:3–11.
- The genotype-phenotype relationships for mutations in the gene for neutrophil elastase, *ELANE*, and outcomes for severe chronic and cyclic neutropenia.